Falco Luigi, Valente Fabio, De Falco Aldo, Barbato Raffaele, Marotta Luigi, Soviero Davide, Cantiello Luigi Mauro, Contaldi Carla, Brescia Benedetta, Coscioni Enrico, Pacileo Giuseppe, Masarone Daniele
Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy.
Department of Advanced Biomedical Sciences, University of Naples "Federico II", 80131 Naples, Italy.
J Cardiovasc Dev Dis. 2024 Jun 23;11(7):187. doi: 10.3390/jcdd11070187.
Heart failure (HF) is a complex and progressive disease marked by substantial morbidity and mortality rates, frequent episodes of decompensation, and a reduced quality of life (QoL), with severe financial burden on healthcare systems. In recent years, several large-scale randomized clinical trials (RCTs) have widely expanded the therapeutic armamentarium, underlining additional benefits and the feasibility of rapid titration regimens. This notwithstanding, mortality is not declining, and hospitalizations are constantly increasing. It is widely acknowledged that even with guideline-directed medical therapy (GDMT) on board, HF patients have a prohibitive residual risk, which highlights the need for innovative treatment options. In this scenario, groundbreaking devices targeting valvular, structural, and autonomic abnormalities have become crucial tools in HF management. This has led to a full-fledged translational boost with several novel devices in development. Thus, the aim of this review is to provide an update on both approved and investigated devices.
心力衰竭（HF）是一种复杂的进行性疾病，其特征是发病率和死亡率高、频繁失代偿发作以及生活质量（QoL）下降，给医疗系统带来沉重的经济负担。近年来，几项大规模随机临床试验（RCT）广泛扩充了治疗手段，凸显了额外的益处以及快速滴定方案的可行性。尽管如此，死亡率并未下降，住院率却持续上升。人们普遍认识到，即使采用了指南指导的药物治疗（GDMT），HF患者仍存在极高的残余风险，这凸显了创新治疗方案的必要性。在这种情况下，针对瓣膜、结构和自主神经异常的突破性设备已成为HF管理中的关键工具。这推动了多项新型设备的全面转化发展。因此，本综述的目的是提供关于已获批和正在研究的设备的最新信息。
